x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:24:43

ESMO 2025

OncoPharm ·

2025/10/23

This week's episode recaps some highlights from ESMO 2025:1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery 2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer 3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer 4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer 5. Dynamic-III: ctDNA guide de-escalation or escalation of chemotherapy in stage III colon cancer 6. HARMONi-6: an

en

00:07:59

IL-2

OncoPharm ·

2025/10/16

IL-2, one of the founding fathers of our current immunotherapy landscape, is discussed.

en

00:12:03

Maintenance Therapy in Small Cell Lung Cancer

OncoPharm ·

2025/10/09

Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab?IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6 DeLLphi-303 (phase 1b maintenance tarlatamab + ICI): https://doi.org/10.1016/S1470-2045(25)00480-2

en

00:11:09

PARAMOUNT - Maintenance Pemetrexed

OncoPharm ·

2025/10/03

Our Landmarks of OncoPharm series returns to discuss PARAMOUNT, a landmark study that helped solidify the role of maintenance pemetrexed in NSCLC.

en

00:18:00

SC Pembro, Biotin, P5-yr POLARIX data

OncoPharm ·

2025/09/25

The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use.Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://doi.org/10.1200/OP-25-00693 POLARIX 5-year Data: https://doi.org/10.1200/JCO-25-00925

en

00:12:33

ALASCCA

OncoPharm ·

2025/09/21

We discuss the ALASCCA study (Adjuvant Low-doseASpirin in Colorectal CAncer

en

00:13:41

EGFRm NSCLC Updates

OncoPharm ·

2025/09/11

The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC.1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling! 2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of

en

00:10:25

Time to Cilta-Cel-ebrate?

OncoPharm ·

2025/09/04

The 5-year+ follow-up from CARTITUDE-1 has people asking if cilta-cel can cure multiple myeloma? We discuss this data and the broad comparison to the other BCMA-targeting CAR-T product, idi-cel and a recent comparison on plasma cell leukemia.CARTITUDE-1 Long-Term F/U: https://doi.org/10.1200/JCO-25-00760 Cilta-cel & ide-cel in plasma cell leukemia: https://doi.org/10.1182/bloodadvances.2025016966

en

00:11:25

RNA Vaccine Potential as a Cancer Treatment

OncoPharm ·

2025/08/28

The potential breakthrough in RNA vaccine technology has been increasingly discussed on social media. This episode looks at one promising study and its early, early results so far.UF GBM study: https://doi.org/10.1016/j.cell.2024.04.003 RNA Treatment Vaccine Review: https://doi.org/10.1002/ctm2.1384

en

00:17:47

Venetoclax Dosing & APOLLO

OncoPharm ·

2025/08/21

Malignant Hematology Updates:Venetoclax dosing strategies continue to evolve HMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640 HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914 Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723 APOLLO: https://doi.org/10.1200/JCO-25-00535 Iland APOLLO editorial: https://doi.org/10.1200/JCO-25-01496 ctDNA assessment vs. PET in Large B-Cell Lymphoma: https://doi.org/10.1200/JCO-25-01534

en

00:12:07

Zongertinib

OncoPharm ·

2025/08/14

A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.

en

00:11:30

Dordaviprone & RCT to prevent ADRs

OncoPharm ·

2025/08/07

This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.Dordaviprone data: https://doi.org/10.1200/jco.23.01134 Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug reaction rates and preventing potential medication errors in hematology-oncology: a randomized controlled trial. JCO Oncology Practice:

en

00:10:21

ProMACE-CytaBOM

OncoPharm ·

2025/07/31

More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdf RCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

en

00:11:19

Testicular Cancer in a Nutshell

OncoPharm ·

2025/07/17

A brief overview of testicular cancer

en

00:11:12

Supportive Care Updates

OncoPharm ·

2025/07/10

A few supportive care updates:1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi. Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode Link: https://doi.org/10.1200/OP-25-00100 2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes Link: https://doi.org/10.1016/S1470-2045(25)00231-1

en

00:09:36

Linvoseltamab & sunvozertinib

OncoPharm ·

2025/07/03

Two new drug approvals to talk about (after I misplaced my notes!)

en

00:09:53

Antiandrogen Withdrawal

OncoPharm ·

2025/06/25

Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?

en

00:27:37

June 2025 Updates

OncoPharm ·

2025/06/19

A plethora of recent updates:-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689) -Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib -Pirtobrutinib improves PFS in CLL -Zanubrutinib has a new dosage form on the way -Another mitomycin product approved with "reverse thermal properties" -A new regimen for FL of tafasitamab/rituximab/lenalidomide -A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

en

00:14:15

ASCO 2025

OncoPharm ·

2025/06/05

A recap of notable updates from ASCO 20251. Destiny-Breast09 2. BREAKWATER 3. ATOMIC 4. Delphi-304 5. CM 816 OS update 6. C-POST 7. Matterhorn

en

00:11:17

CLEOPATRA

OncoPharm ·

2025/05/29

Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.

en

420 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter